Evidence map›Paper›PMID 33831214›Full record

ArticleInteractive cardiovascular and thoracic surgery2021

Early commercial experience with a newly designed balloon-expandable transcatheter heart valve: 30-day outcomes and implications of preprocedural computed tomography.

Andreas Schaefer, Fabienne Plassmeier, Niklas Schofer, Lukas Vogel, Sebastian Ludwig, Yvonne Schneeberger, Matthias Linder, Till Demal, Moritz Seiffert, Stefan Blankenberg and 3 more

Open access · greenAbstract read
In one paragraph

Article in Interactive cardiovascular and thoracic surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Andreas SchaeferDepartment of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Fabienne PlassmeierDepartment of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Niklas SchoferDepartment of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Lukas VogelDepartment of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Sebastian LudwigDepartment of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Yvonne SchneebergerDepartment of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Matthias LinderDepartment of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Till DemalDepartment of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Moritz SeiffertDepartment of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Stefan BlankenbergDepartment of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Hermann ReichenspurnerDepartment of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Dirk WestermannDepartment of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Lenard ConradiDepartment of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Universität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe herein report a single-centre experience with the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve implantation (TAVI) system.

methodsBetween March 2019 and January 2020, a total of 79 consecutive patients received transfemoral TAVI using the SAPIEN 3 Ultra device. Data were retrospectively analysed according to updated Valve Academic Research Consortium-2 definitions. Detailed analysis of multislice computed tomography data was conducted to identify potential predictors for permanent pacemaker (PPM) implantation and residual paravalvular leakage (PVL) post TAVI.

resultsDevice success and early safety were 97.5% (77/79) and 94.9% (75/79) with resulting transvalvular peak/mean pressure gradients of 21.1 ± 8.2/10.9 ± 4.4 and PVL >mild in 0/79 patients (0%). Mild PVL was seen in 18.9% (15/79) of cases. Thirty-day mortality was 2.5% (2/79). The Valve Academic Research Consortium-2 adjudicated clinical end points disabling stroke, acute kidney injury and myocardial infarction occurred in 1.3% (1/79), 5.1% (4/79) and 0% (0/79) of patients. Postprocedural PPM implantation was necessary in 7.6% (6/79) of patients. Multislice computed tomography analysis revealed significantly higher calcium amounts of the right coronary cusp in patients in need for postprocedural PPM implantation and a higher eccentricity index in patients with postinterventional mild PVL.

conclusionsFirst experience with this newly designed balloon-expandable-transcatheter heart valve demonstrates adequate 30-day outcomes and haemodynamic results with low mortality, low rates of PPM implantation and no residual PVL >mild. The herein-presented multislice computed tomography values with an elevated risk for PPM implantation and residual mild PVL may help to further improve outcomes with this particular transcatheter heart valve in TAVI procedures.

Indexed as

AgedAged, 80 and overAortic Valve StenosisCommerceFemaleFluoroscopyFollow-Up StudiesHeart Valve ProsthesisHumansMaleMultidetector Computed TomographyProsthesis DesignRetrospective StudiesTranscatheter Aortic Valve ReplacementTreatment OutcomeBalloon-expandableTranscatheter aortic valve implantation Transcatheter aortic valve replacementTranscatheter valve therapyValve disease

Identifiers

PMID33831214
PMCPMC8906766
OpenAlexW3110113870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.